JP2022553329A - アルツハイマー病を治療するための抗ベータ－アミロイド抗体 - Google Patents

アルツハイマー病を治療するための抗ベータ－アミロイド抗体 Download PDF

Info

Publication number
JP2022553329A
JP2022553329A JP2022523595A JP2022523595A JP2022553329A JP 2022553329 A JP2022553329 A JP 2022553329A JP 2022523595 A JP2022523595 A JP 2022523595A JP 2022523595 A JP2022523595 A JP 2022523595A JP 2022553329 A JP2022553329 A JP 2022553329A
Authority
JP
Japan
Prior art keywords
antibody
subject
tau
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553329A5 (https=
Inventor
ヘーベルライン， サマンサ バッド
イン ティアン，
ローラ ニセンバウム，
ラジ ラジャゴビンダン，
ガーシャム デント，
ジョン ビーバー，
エドワード プロウェイ，
ティエリー ビュシエール，
ロジャー ニッチュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2022553329A publication Critical patent/JP2022553329A/ja
Publication of JP2022553329A5 publication Critical patent/JP2022553329A5/ja
Priority to JP2025181171A priority Critical patent/JP2026012271A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022523595A 2019-10-22 2020-10-21 アルツハイマー病を治療するための抗ベータ－アミロイド抗体 Pending JP2022553329A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181171A JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
US62/924,633 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181171A Division JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Publications (2)

Publication Number Publication Date
JP2022553329A true JP2022553329A (ja) 2022-12-22
JP2022553329A5 JP2022553329A5 (https=) 2023-10-30

Family

ID=73344157

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523595A Pending JP2022553329A (ja) 2019-10-22 2020-10-21 アルツハイマー病を治療するための抗ベータ－アミロイド抗体
JP2025181171A Pending JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181171A Pending JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ－アミロイド抗体

Country Status (13)

Country Link
US (1) US20220372123A1 (https=)
EP (1) EP4048695A1 (https=)
JP (2) JP2022553329A (https=)
KR (1) KR20220084095A (https=)
CN (1) CN114599393A (https=)
AU (1) AU2020371612A1 (https=)
BR (1) BR112022007595A2 (https=)
CA (1) CA3158513A1 (https=)
CO (1) CO2022004902A2 (https=)
IL (1) IL292363A (https=)
JO (1) JOP20220092A1 (https=)
MX (1) MX2022004678A (https=)
WO (1) WO2021081101A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501945A (ja) * 2007-10-17 2011-01-20 ヤンセン アルツハイマー イミュノセラピー ＡｐｏＥ状態に依存する免疫療法レジメ
JP2016501247A (ja) * 2012-12-07 2016-01-18 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー 抗Ａβ抗体を使用して脳アミロイド斑を減少させる方法
JP2019517540A (ja) * 2016-06-07 2019-06-24 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー アルツハイマー病を治療する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008141321A1 (en) * 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
EP2598882B1 (en) * 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501945A (ja) * 2007-10-17 2011-01-20 ヤンセン アルツハイマー イミュノセラピー ＡｐｏＥ状態に依存する免疫療法レジメ
JP2016501247A (ja) * 2012-12-07 2016-01-18 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー 抗Ａβ抗体を使用して脳アミロイド斑を減少させる方法
JP2019517540A (ja) * 2016-06-07 2019-06-24 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー アルツハイマー病を治療する方法

Also Published As

Publication number Publication date
WO2021081101A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23
CO2022004902A2 (es) 2022-07-08
BR112022007595A2 (pt) 2022-08-23
KR20220084095A (ko) 2022-06-21
JOP20220092A1 (ar) 2023-01-30
CN114599393A (zh) 2022-06-07
EP4048695A1 (en) 2022-08-31
US20220372123A1 (en) 2022-11-24
MX2022004678A (es) 2022-08-15

Similar Documents

Publication Publication Date Title
JP2022553329A (ja) アルツハイマー病を治療するための抗ベータ－アミロイド抗体
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
EP4626918A1 (en) Methods of treatment using a tau pet level
KR20240115910A (ko) 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
JP2024540294A (ja) アルツハイマー病を治療するための方法
JP2024532438A (ja) 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法
TW202434629A (zh) 以抗類澱粉β (ABETA)抗體治療神經病症之方法
TW202313111A (zh) 治療阿茲海默症之方法
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
NZ788486A (en) Methods for treating Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250625

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250910